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Abstract
Background: Osteosarcoma (OS) is the most common type of bone malignancy. Many studies have attempted to find the associa-
tion between microRNAs and cancer-associated processes. Alterations in miRNA expression through genetic or epigenetic changes,
impairment of transcription factors, and ectopic expression of miRNAs induce the development and progression of cancer. Al-
though miR-135b has been thoroughly documented as an oncogene in the majority of studies, some controversies remain about the
conflicting role of miR-135b as a tumor-suppressor.
Objectives: The present study aimed at investigating the oncogenic and/or tumor-suppressing role of miR-135b in human OS.
Methods: In this study, 21 OS tissue samples, along with 21 adjacent bone tissues (normal) as control specimens were collected to
analyze the expression of miR-135b. The Saos2 cell-line was transiently transfected with the miR-135b mimic and inhibitor to assess its
effect on two critical transcription factors, namely FOXO-1 and c-Myc. qRT-PCR was performed to quantify the expression of miR-135b
in both OS tissues and the Saos2 cell-line. The MTT, cell migration, and cell invasion assays were used to characterize the miR-135b
function. The western blot analysis was carried out to monitor the targets of miR-135b. Finally, the changes in cellular functions such
as migration and invasion, following the transfection of miR-135b mimic and inhibitor, were verified.
Results: The results showed that in comparison with the adjacent normal bone tissues, the expression of miR-135b was higher in OS
tissue samples, which inversely correlated with the expression rate of FOXO-1, whereas the expression of c-Myc had a direct relation-
ship to miR-135b expression. Functionally, the miR-135b mimic led to an increase in cell proliferation, invasion, and migration of OS
cancer cells.
Conclusions: MiR-135b induces the proliferation and invasion of OS cells by the degradation of FOXO-1 and upregulation of c-Myc.
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1. Background
Osteosarcoma (OS), known as osteogenic sarcoma, is
an aggressive and primary bone tumor with an incidence
rate of 4 to 5 cases per million, affecting children and ado-
lescents (1-5). More importantly, it accounts for 19% of all
malignant tumors of bone (6) with a higher prevalence
in young males compared with young females (5), and its
etiology is still opaque (4, 7). It affects the metaphysis of
long bones, such as the distal femur, and it seems that
rapid bone growth occurring in adolescents is related to
the promotion of malignancy (8). Although there is still a
controversy about the origin of OS, accumulative evidence
has shown that it is regarded as a differentiation disease
caused by genetic changes, leading to the disruption of the
differentiation of mesenchymal stem cells into osteoblast
(1). OS, as heterogenic cancer, is characterized by broad
ranges of the genomic instability, increased abnormality
in karyotypes, and multiple genomic aberrations, includ-
ing copy number gains and losses in several chromosomes
(2). Calin et al. demonstrated, for the first time, the rela-
tionship between the susceptibility of various cancers and
miRNAs in 2002 (9, 10).
Recent studies have indicated that non-coding RNAs,
such as microRNA with conserved sequences exert essen-
tial roles in both normal physiological processes, includ-
ing the development, differentiation, metabolism, and
proliferation, as well as disease progression that include
malignant tumors (2, 7, 10, 11). Several lines of evidence
show that the dysregulation of miRNAs is associated with
the initiation and disease progression of tumors, along
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with their invasion, metastasis, and chemo-resistance;
however, their contribution to the development of OS is
still unclear (7, 10, 12). MiRNAs mainly consist of 22 nu-
cleotides involved in RNA silencing by post-transcriptional
regulation of gene expression, changing the stability of
specific mRNAs, or obstructing the translation of some mR-
NAs. Hence, any alteration in the expression of miRNAs
may influence the expression of tumor-suppressor and
oncogene genes (4, 9, 13-16). Gao et al. studied the role of
miRNA expression in the development of OS (2). MiR-135b
plays a functional role in the normal differentiation of os-
teoblasts (1, 17, 18). Also, the presence of miR-135b in the pla-
centa is capable of regulating the growth rate of its cells
(19). It has been revealed that miR-135b contributes to the
differentiation of mesenchymal cells into bone and muscle
cells during embryonic development (20). Moreover, the
decreased expression of miRNAs is necessary for the nor-
mal mineralization of osteoblast cells (16).
Recent data suggest that FOXO-1, one of the FOXO fam-
ily members of the transcription factors, participates in a
variety of biological events, such as cell proliferation, apop-
tosis, stress response, and DNA damage response. Several
studies have shown that FOXO-1 is involved in many types
of cancers (21-23). There is strong evidence indicating that
the upregulated expression of c-Myc is a major factor in the
initiation of OS (23, 24). c-Myc, as an oncogene gene, is over-
expressed in many types of cancers, and it contributes to
cell migration, cell invasion, metastasis, and cell cycle (25).
On the other hand, although FOXO expression is frequently
reduced in numerous types of cancers, the increased ex-
pression of the transcription factor c-Myc has been further
reported (26). c-Myc, as a transcription factor, is a pivotal
player in different cellular processes, including cell migra-
tion, growth, and proliferation (27, 28).
In the case of cancer, the expression of miR-135b is im-
paired, resulting in cancer cell promotion, migration, and
invasion (20). Mechanistically, its oncogenic function is
mediated via the repression of some crucial components
of the Hippo pathway, which controls the organ size in
Drosophila melanogaster and tumorigenesis in mammals
(19). Although a large proportion of the available data
agrees with the oncogenic role of miR-135b, its function in
the context of cancer is highly controversial. For instance,
it has been shown that miR-135b promotes several types
of cancers, such as breast and lung cancers (29, 30). How-
ever, contradictory results have demonstrated that miR-
135b suppresses the invasion of prostate cancer cells and
abrogates the chemoresistance of lung cancer cells (31, 32).
2. Objectives
The current research aimed at evaluating the precise
role of miRNA-135b in the development of OS, thereby de-
termining the targets of miR-135b and their impact on cell
proliferation, cell invasion, and cell migration.
3. Methods
3.1. Sample Collection
In this study, 21 OS tissue samples, along with 21 adja-
cent normal bone tissues, as control specimens were ob-
tained from patients with a definite diagnosis of OS. Pa-
tients were referred to the Shefa Hospital (Tehran, Iran) be-
tween 2015 and 2018. The collected tissue samples were
stored in liquid nitrogen at -80°C until the analysis.
3.2. Cell Culture
The Saos-2 cell-line was procured from the cell bank
of the Culture Collection of Pasteur Institute (Tehran,
Iran). The cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) (Gibco, Carlsbad, CA, USA) that was sup-
plemented with 10% fetal bovine serum (Gibco, Carlsbad,
CA, USA) and penicillin/streptomycin antibiotics (Gibco,
Carlsbad, CA, USA). The cells were incubated in an incuba-
tor with 5% CO2 at 37°C.
3.3. Cell Transfection
MiR-135b inhibitor, miR-135b mimic, and the controls
were provided by the BIONEER company (Daejeon, South
Korea). The concentration of miRNAs employed in this re-
search was 20 nmol/L. The process of the cell transfection
was facilitated by polyethyleneimine (PEI) that compacts
the DNA molecule into particles with positive charges,
leading to the binding of the desired molecules to anionic
cell surface residues and uptake of them by the cell mem-
brane under a cellular phenomenon called endocytosis.
The experiments were carried out in triplicate.
3.4. Real-Time PCR
The miRNA contents of the cultured cells and isolated
tissues were extracted, using the miRNeasy Mini kit (QIA-
GEN, Cat.No.217004). The extracted miRNAs were applied
for the synthesis of complementary DNA (cDNA), using the
miScript II RT Kit (QIAGEN, Cat.No.218161). The synthesized
cDNA samples were used for the amplification of the tar-
get genes, using the miScript SYBR Green PCR Kit (QIAGEN,
Cat.No.218061). The primers used for the analysis of the
expression of miR-135b, as well as the endogenous control
RNU6, were obtained from Tag Copenhagen A/S (Denmark).
A miRNA-specific forward primer and a universal reverse
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primer were applied for the subsequent qPCR step. The se-
quences of the forward primers used in our study were as
follows; miR-135b: 5’-CGTATGGCTTTTCATTCCTATGT-3’, U6:
5’-CGCAAGGATGACACGCAA ATT C-3’, and the sequence of
the miScript Universal Primer in the miScript SYBR Green
kit is proprietary. The relative expression of miRNAs was
determined according to the ∆∆CT method.
3.5. Cell Proliferation Assay
For the comparison of the rate of cell proliferation rate
between untransfected cells and transfected cells, the MTT
assay was utilized. In brief, 15 × 103 cells per well were
seeded onto a 96-well microplate and incubated for 24
hours. Next, the cell transfection was conducted, using
PEI; then the cells were incubated for 48 hours. Afterward,
the cell culture medium was exchanged with the 10% MTT
solution (5 mg/mL thiazolyl blue tetrazolium bromide in
PBS; Sigma. Aldrich), and the cells were incubated at 37°C
for 4 hours. Consequently, the reaction was terminated by
the addition of 100 µL DMSO to dissolve the produced for-
mazan crystals. The optical absorbance of the samples was
read at a wavelength of 570 nm, using a microplate reader
(Biotek Instruments, Inc. Winooski, VT, USA).
3.6. Cell Invasion Assay
For the comparison of the invasiveness between un-
transfected cells and transfected cells, the Cell Invasion As-
say Kit (Biovision) was utilized according to the manufac-
turer’s recommendations. In brief, 24 hours after the trans-
fection process, cells were seeded on the upper chamber,
where the ECMatrix TM gel was pre-coated for 24 hours.
Afterward, 700 µL of the 10% FBS-containing medium was
supplemented with the lower chamber as a chemoattrac-
tant agent. The cells were, then, incubated at 37°C in 5% CO2
for 48 hours. Next, non-invading cells were removed, using
a swab, while cells migrated into the bottom of the mem-
brane were fixed with 3.7% formaldehyde. Next, the cells
were permeabilized by 100% methanol and, finally, stained
with the Giemsa solution. For the quantification of the as-
say, stained cells were counted in multiple fields under a
light microscope, and the mean numbers of the cells were
reported.
3.7. Cell Migration Assay
The cell migration technique was conducted according
to the scratch test. In brief, 24 hours after the transfection
procedure, mitomycin C was added to the culture media
to prevent further cell division. After 2 hours, an artificial
gap was produced, using a 100 µL pipette tip (scratching).
Then, the cell culture medium was exchanged with fresh
DMEM that was devoid of fetal bovine serum. Regularly,
cells on the edge of the created gap tend to move toward
the groove to fill-in the gap until new cell-cell contact is es-
tablished. For the visualization of the cell migration pro-
cess, images were taken at 0 and 24 hours. The ImageJ soft-
ware (NIH, Bethesda, USA) was employed for the calcula-
tion of cell migration.
3.8. Western Blot
For the extraction of the protein contents of the cells,
transfected cells were lysed through radioimmunoprecip-
itation assay buffer (RIPA). Afterward, the concentration of
the protein content of each sample was determined, us-
ing the BCA Protein Assay Kit (Thermo Fisher Scientific Inc.
USA). The equivalent amount of extracted proteins were
loaded on 10% SDS-PAGE and electrophoretically separated
and, then, transferred onto a polyvinylidene difluoride
(PDVF) membrane (Amersham, Buckinghamshire, UK). The
PVDF membrane was blocked by 5% skim milk in Tris-
buffered saline containing 0.1 % Tween 20 for 1 hour. Next,
the membrane was incubated with specific primary anti-
bodies against c-MYC and FOXO-1 proteins (Rabbit mono-
clonal antibodies, Cell Signaling Technology, Danvers, MA,
USA) overnight. The membrane was, then, washed 3 times
and incubated with HRP-conjugated goat anti-rabbit IgG
secondary antibody (Cell Signaling Technology, Danvers,
MA, USA) at room temperature for 1 hour. The probed anti-
bodies were, then, visualized by the ECL detection reagent
(Roche, Basel, Switzerland) and, subsequently, the signal
intensity of the protein bands was quantified, using the
ImageJ software (NIH, Bethesda, USA).
3.9. Statistical Analysis
The statistical analysis was conducted by the SPSS soft-
ware version 21. Data were expressed as the means ± stan-
dard deviation (mean ± SD). The differences between the
two experimental groups were analyzed by the Student’s
t test, while for multiple comparisons, one-way analysis
of variance (ANOVA) was utilized, followed by Tukey’s post
hoc test. The P value of less than 0.05 was statistically con-
sidered significant and each experiment was performed at
least 3 times.
4. Results
4.1. Increased Level of miR-135b Expression in OS
For the assessment of the role of miR-135b in the devel-
opment of OS, the expression of miR-135b was analyzed in
21 paired OS and adjacent normal bone tissues, using the
qRT-PCR method. The results revealed that the expression
level of miR-135b was significantly higher in cancerous tis-
sues compared with adjacent normal bone tissues (Figure
1).
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Figure 1. The relative expression of miR-135b was determined in human osteosar-
coma tissues obtained from patients, as well as their adjacent healthy bone tissues,
using the qRT-PCR technique (*, P < 0.0001).
4.2. The miR-135b Expression After the Transfection of OS Cell-
Line
The findings of this study indicated that the expression
level of miR-135b was increased by 100 folds in the Saos-
2 cell-line transfected with miR-135b mimic, while the ex-
pression level of miR-135b was significantly decreased in
the Saos-2 cell-line transfected with anti-miR-135b (Figure
2A). The efficiency of the transfection procedure was exam-
ined under an Olympus (DP70) microscope (Figure 2B).
4.3. MiR-135b Induces Cell Proliferation in the Saos-2 Cell-Line
The possible tumorigenic or tumor-suppressive roles
of miR-135b in OS were assessed by the in vitro functional
analyses, including MTT and cell viability assays. The MTT
assay revealed that Saos-2 cells transfected with miR-135b
mimic exhibited higher proliferative activity in compari-
son with cells transfected with scrambled miRNA. Further-
more, the downregulation of miR-135b in Saos-2 cells after
transfection with anti-miR-135b was able to decrease cell
proliferation (Figure 3). These results indicate that miR-
135b exerts an oncogenic function when introduced into
these cells.
4.4. Overexpression of miR-135b Accelerates Migration and In-
vasion of Saos-2 Cells
The results of the scratch assay (wound healing assay)
showed that the overexpression of miR-135b significantly
increased the migration of Saos-2 cells. Cells transfected
with the miR-135b mimic have more migratory potential
than the cells transfected with control and scrambled miR-
NAs. Of note, the miR-135b inhibitor markedly decreased
the cell migration of Saos-2 cells at 24 hours of the trans-
fection process (Figure 4A). The distance of cell migration
was calculated to quantitatively determine the migration
ability of the cells (Figure 4B). Consistently, the overexpres-
sion of miR-135b induced the cell invasion measured by the
transwell assay (Figure 5).
4.5. MiR-135b Targets FOXO-1 in Saos-2 Cell-Line
The Saos-2 cell-line was transiently transfected with the
miR-135b mimic and inhibitor. The western blot analysis
was performed to detect FOXO-1 at the protein level. Com-
pared with the negative control group, the protein level of
FOXO-1 was significantly diminished and increased in re-
sponse to the miR-135b mimic and inhibitor, respectively,
when applied for Saos-2 cells (Figure 6A). These results indi-
cated that the FOXO-1 protein contains some binding sites
for miR-135b.
4.6. MiR-135b Induces c-Myc Expression in Saos-2 Cell-Line
The Saos-2 cell-line was transiently transfected with the
miR-135b mimic and inhibitor. The findings of the present
study demonstrated that in comparison with the nega-
tive control group, the protein level of c-Myc was signifi-
cantly increased and decreased in response to the miR-135b
mimic and inhibitor, respectively (Figure 6B). These results
showed that the c-Myc protein is upregulated in response
to the introduction of miR-135b into the cells.
5. Discussion
The dysregulation of miRNAs has been documented in
a wide range of malignancies (14, 16, 33-35). The pattern
of alterations in the expression levels of miRNAs is widely
used in cancerous tissues for diagnostic and prognostic
purposes, as well as finding novel biomarkers for the early
screening of patients with cancer (36).
Herein, in line with previous studies, we showed that
the expression of miR-135b is aberrantly upregulated in pri-
mary tumors of patients with OS compared with the adja-
cent normal tissues (14, 16, 35, 36). The change in the expres-
sion of miR-135b affects some molecular pathways involved
in the onset and progression of neoplasia (4). The prolif-
eration, invasion, and metastasis are 3 cellular events that
4 Int J Cancer Manag. In Press(In Press):e101577.
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Figure 2. A, The relative expression of miR-135b was assessed in Saos-2 cells transfected with miR-135b mimic, inhibitor, and controls, using the qRT-PCR method; B, the suc-















































Figure 3. MiR-135b increased the proliferation of Saos-2 cells. The proliferation pat-
tern of Saos-2 cells transfected with miR-135b mimic, inhibitor, and controls, using
MTT assays (*, P < 0.001).
are critical for cancer progression. This research indicated
that miR-135b plays a decisive role in the proliferation, inva-
sion, and metastasis of cancer cells. We found that the ec-
topic expression of miR-135b promoted cell proliferation,
invasion, and metastasis when assessed in vitro. In con-
trast, a significant reduction was detected in cell prolifer-
ation, invasion, and metastasis in the presence of endoge-
nous miR-135b inhibitor. Hence, it can be inferred that miR-
135b can enhance cell proliferation, invasion, and metasta-
sis in OS cells. Consistently, Lin et al. demonstrated that
the expression of miR-135b increases cell invasiveness and
metastasis (11, 19).
In the current study, the results have shown that the
function of miR-135b is mechanistically dependent on the
regulation of the gene expression of FOXO-1 and c-Myc. In
detail, we found that the transfection of OS cells with miR-
135b mimic suppressed FOXO-1 expression, which in turn
led to the induction of proliferation, invasion, and metas-
tasis of the cancer cells. FOXO-1, one of the FOXO family
members of the transcription factors, plays a critical role
in the proliferation and causes the repression of the cell
cycle (3, 37-39) and, more importantly, it is involved in os-
teocyte survival (3). It has been suggested that the family
members of FOXO are oncogenic regulators (40) or tumor-
suppressors in a variety of cancers (39). The bioinformat-
ics analysis showed that FOXO-1 is a direct target for miR-
135b in OS (14). There is tantalizing evidence showing that
miR-135b is one of the potential miRNAs that can downreg-
ulate FOXO-1 and promote cancer cell proliferation (41). In
parallel, Guan H et al. (3) indicated that FOXO-1 inhibition
caused an increase in cell proliferation.
For the determination of the precise role of miR-135b,
we evaluated the expression of c-Myc along with FOXO-1.
The results of this study showed that the upregulation and
downregulation of this miRNA are associated with an in-
crease and a decrease in the protein level of c-Myc in OS
cells, respectively.
The mechanistic connection of the genetic and epige-
netic alterations with c-Myc activation has been addressed
in numerous cancers (2). It is well-established that the c-
Myc protein is a multifunctional transcription factor that
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Figure 4. MiR-135b increased the migration of Saos2 cells. A, The percentage of the open wound assay at 0 and 24 hours following the scratching process (*, P < 0.05); B, the
effect of the miR-135b mimic and inhibitor on the migration ability of Saos-2 cells was evaluated by the Scratch assay.
plays a pivotal role in regulating cellular processes such as
cell migration and proliferation (42). Hence, its upregula-
tion can increase the rate of these cellular phenomena (42).
Miller et al. (43) demonstrated that miRNAs are potential
regulators of c-Myc that they can post-translationally in-
duce the overexpression of this gene. The overexpression
of c-Myc has been demonstrated in several types of cancers,
as well as its contribution to cancer cell cycle progression,
invasion, migration, and metastasis (25). The aberrant ex-
pression of c-Myc has been implicated in many neoplasms
(44, 45). The uncontrolled expression of c-Myc provides
sufficient energy and substrates for the process of cell pro-
liferation (42, 46). Moreover, its activation is associated
with the progression of some tumors and poor prognosis
(3, 45, 47).
5.1. Conclusions
In conclusion, it seems that miRNA-135b is involved in
growth and the spread of OS in a mechanism dependent on
modulating the expression of both c-Myc and FOXO-1. Al-
though the results of this investigation, along with others,
could partly introduce miRNA-135b as a possible player in
OS pathogenesis, more studies are necessary to clarify the
role of miRNAs in this regard.
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Figure 5. MiR-135b induced the cell invasion in the Saos2 cell-line. A, The percentage of invasive cells was calculated under a light microscope in each group (*, P < 0.05); B,
representative results of the transwell assay that detected the impact of the miR-135b mimic, inhibitor, and control.
Figure 6. MiR-135b targets FOXO-1 and c-Myc in OS cells. A, The protein expression of FOXO-1 in Saos-2 cells transfected with 20 nmol of the miR-135b mimic and inhibitor after
48 hours of the transfection by the western blot analysis; B, the protein expression of c-Myc in Saos-2 cells transfected with 20 nmol of the miR-135b mimic and inhibitor, after
48 hours of the transfection process by the western blot analysis (NC: negative control; *, P < 0.05).
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